Phase 1 RCT of a Hendra virus sG vaccine (HeV-sG-V) against Nipah virus in 192 healthy adults vs placebo: no serious adverse events; mainly mild-to-moderate injection site pain. Two doses were immunogenic (highest with 100 μg 28 days apart); one dose was not sufficient.
RCTn = 192
Frenck et al. Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study